Stock listing
OTC:RGRX RegeneRx Biopharmaceuticals, Inc. Stock
Follow RegeneRx Biopharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:RGRX
$0.0011 USD 0.0000 (0.0%)
Close on Oct 30, 2026
- Day range
- $0.0011 – $0.0011 USDOct 30, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size
- 52-week range
- $0.0002 – $0.1630 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $0 USDMedian day 0 shares · 60 days with no trades · last 3 months, Jul 30, 2026 – Oct 30, 2026

Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OTC:RGRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 251 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.1580 | $0.1580 | $0.0011 | 1,292 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.1610 | $0.1610 | $0.0011 | 252 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | 0.0000 | 0.0% | $0.0011 | $0.0011 | $0.0011 | 0 | |
| $0.0011 | +0.0004 | +57.1% | $0.0011 | $0.0011 | $0.0011 | 726 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 155 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 160 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | 0.0000 | 0.0% | $0.0007 | $0.0007 | $0.0007 | 0 | |
| $0.0007 | +0.0001 | +16.7% | $0.0007 | $0.0007 | $0.0007 | 485 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 |
- Ticker
- OTC:RGRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
RegeneRx Biopharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 8 decks · latest November 2021
Valuation
price Oct 30, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.23
Team and board
Officers
| Officer | Role |
|---|---|
| Allan L. Goldstein | Chairman of our Board of Directors and Chief Scientific Advisor |
Board
| Director | Role |
|---|---|
| Allan L. Goldstein | Chairman of our Board of Directors and Chief Scientific Advisor |
| Alessandro Noseda | Director |
| Don Elsey | Member of our Board of Directors |
| Joseph C. Mcnay | Director |
| Mauro Bove | Member of our Board of Directors |
Events
| Quarter | Results |
|---|---|
| Quarter to Sep 30, 2023 | Nov 10, 2023 |
| Quarter to Jun 30, 2023 | Aug 4, 2023 |
| Q1 2023 | Apr 11, 2023 |
| Q4 2022 | Mar 29, 2023 |
| Q3 2022 | Nov 14, 2022 |
| Q2 2022 | Aug 5, 2022 |
| Q1 2022 | May 17, 2022 |
| Q4 2021 | Mar 30, 2022 |
| Q3 2021 | Nov 12, 2021 |
| Q2 2021 | Aug 6, 2021 |
All 12 quarters
| Quarter | Results |
|---|---|
| Q1 2021 | May 18, 2021 |
| Q4 2020 | Mar 31, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2021) | Shareholder meeting | 17 slides | November 2021 |
| The Fall Investor Summit 2019 | Conference | 18 slides | Sep 16, 2019 |
| Rodman & Renshaw 18th Annual Global Investment Conference 2016 | Conference | 28 slides | Sep 12, 2016 |
| Shareholder Meeting (September 2014) | Shareholder meeting | 15 slides | Sep 15, 2014 |
| Shareholder Meeting (July 2010) | Shareholder meeting | 13 slides | Jul 14, 2010 |
| Investor Presentation (October 2008) | Investor deck | 31 slides | Oct 30, 2008 |
| Shareholder Meeting (July 2008) | Shareholder meeting | 19 slides | Jul 2, 2008 |
| Investor Presentation (January 2006) | Investor deck | 48 slides | Jan 25, 2006 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.8K | 76.8K | 76.8K | 76.8K | 69.7K | 56.7K | 93.3K | 60.6K | 0 | 29.0K |
| Cost of revenue | 65.1K | 81.0K | 143.9K | 237.3K | 203.2K | 367.3K | 938.0K | |||
| Gross profit | 76.8K | -11.4K | -87.3K | -144.0K | -142.6K | -367.3K | -909.0K | |||
| Research and development | 0 | 6.64K | 4.92K | 65.1K | 81.0K | 143.9K | 237.3K | 203.0K | 367.0K | 189.0K |
| Selling, general and administrative | 1.48M | 1.40M | 1.37M | 1.27M | 1.31M | 1.36M | 1.53M | 1.57M | 1.55M | |
| Operating income | -1.40M | -1.33M | -1.29M | -1.26M | -1.32M | -1.44M | -1.67M | -1.71M | -1.56M | |
| Depreciation and amortization | 1.42K | 2.75K | 3.05K | 3.33K | 3.40K | 4.82K | ||||
| EBITDA | -1.26M | -1.32M | -1.44M | -1.67M | -1.71M | -1.55M | ||||
| Interest expense | 325.6K | 324.9K | 232.6K | 153.4K | 87.3K | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -1.73M | -1.60M | -1.52M | -1.40M | -1.99M | 385.1K | 229.1K | -5.27M | -2.75M | |
| Income tax | 0 | 98.6K | 0 | 0 | 0 | |||||
| Net income | -1.73M | -1.60M | -1.52M | -1.40M | -1.99M | 286.5K | 229.1K | -5.27M | -2.75M | |
| Earnings per share, basic | -1.20 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 290.9K | 1.23M | 427.9K | 639.9K | 237.3K | 181.7K | 769.5K | 317.6K | 844.0K | 6.00K |
| Current assets | 306.9K | 1.25M | 477.8K | 681.6K | 273.9K | 217.2K | 849.4K | 341.9K | 930.6K | |
| Property, plant and equipment | 27.7K | 68.2K | 24.5K | 1.42K | 4.17K | 7.22K | 10.5K | 13.0K | 4.00K | |
| Total assets | 382.2K | 1.28M | 551.8K | 711.8K | 281.0K | 227.1K | 862.4K | 358.2K | 949.0K | 43.0K |
| Accounts payable | 63.8K | 63.6K | 39.3K | 43.7K | 92.4K | 66.5K | 75.7K | 141.1K | 233.0K | 577.0K |
| Current liabilities | 553.7K | 429.9K | 399.6K | 242.5K | 315.0K | 2.15M | 659.8K | 359.0K | 410.0K | 616.0K |
| Long-term debt | 1.37M | 1.14M | 923.8K | 708.1K | 43.8K | 512.0K | 688.9K | 566.0K | 432.0K | |
| Total liabilities | 3.83M | 3.51M | 3.38M | 3.05M | 2.49M | 4.34M | 6.93M | 7.10M | 2.66M | 1.66M |
| Shareholders' equity | -3.45M | -2.23M | -2.82M | -2.34M | -2.21M | -4.12M | -6.07M | -6.74M | -1.71M | -1.62M |
| Shares outstanding | 1.44M | 143.5M | 133.4M | 131.5M | 128.4M | 109.8M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -940.7K | -990.3K | -1.01M | -1.14M | -888.3K | -663.1K | -1.07M | -525.3K | -1.70M | |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.08K | -13.0K | 0 |
| Free cash flow | -940.7K | -990.3K | -1.01M | -1.14M | -888.3K | -663.1K | -1.07M | -526.4K | -1.72M | |
| Cash from investing | -1.08K | -13.3K | ||||||||
| Cash from financing | 0 | 1.79M | 794.9K | 1.54M | 943.8K | 75.3K | 1.52M | 1.52M | 2.56M | 646.0K |
| Share buybacks | 75.3K | 1.52M | 1.52M | 2.50M | ||||||
| Change in cash | -940.7K | 803.7K | -212.0K | 402.7K | 55.6K | -587.8K | 451.9K | -526.4K | 837.7K |
Cap table
Built by 6ix from RegeneRx Biopharmaceuticals, Inc.’s releases
- Common shares
- 1,496,966
- Fully diluted
- 1,496,966
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,496,966 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,496,966 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Don Elsey Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023); Lyra Therapeutics, Inc. (CFO, Treasurer & Secretary · Apr 30, 2020 – Feb 8, 2021 · Past); CapForce Inc. (Director · Feb 21, 2019 – Jun 7, 2023 · Past); Senseonics Holdings, Inc. (CFO, Secretary and Treasurer · Apr 12, 2016 – Feb 2, 2018 · Past) | Member of our Board of Directors · Since at least Sep 1, 2017 |
| Alessandro Noseda | Director · Since at least May 15, 2019 |
| Allan L. Goldstein | Chairman of our Board of Directors and Chief Scientific Advisor · Since at least Oct 19, 2017 |
| Joseph C. Mcnay | Director · Since at least Nov 5, 2026 |
| Mauro Bove | Member of our Board of Directors · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about RegeneRx Biopharmaceuticals, Inc.